Last updated on July 2019

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]


Brief description of study

The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.

Detailed Study Description

The drug being tested in this survey is called vedolizumab for IV infusion 300 mg. This drug is being tested to treat patients who have CD.

This survey is an observational (non-interventional) study and will look at the long-term safety and effectiveness of vedolizumab for IV infusion 300 mg in the routine clinical setting. The planned number of observed patients will be approximately 300.

This multi-center observational trial will be conducted in Japan.

Clinical Study Identifier: NCT04002180

Find a site near you

Start Over

Takeda Selected Site

Tokyo, Japan
1.79miles
  Connect »